CJC 1295 With DAC Peptide – 5MG

CJC‑1295 With DAC  5 mg | Long‑Acting GHRH Analogue for In‑Vitro Research | Research Use Only

CJC‑1295 With DAC is a growth hormone–releasing hormone (GHRH) analogue featuring a Drug Affinity Complex (DAC) modification that extends peptide stability and receptor‑engagement duration in controlled in‑vitro GH‑axis research. Supplied as a 5 mg lyophilised vial for laboratory research only. Not for human use.

What is CJC‑1295 With DAC?

CJC‑1295 With DAC is the long‑acting variant of the GHRH analogue family. The DAC modification supports:

• Extended receptor‑adjacent signalling
• Prolonged ligand–receptor interaction windows
• Enhanced stability in biochemical and cell‑based systems
• Long‑duration cAMP/PKA pathway profiling
• GH‑axis mechanistic and SAR investigations

All applications are restricted to non‑clinical, in‑vitro laboratory environments.

Key Features

• Long‑acting GHRH analogue featuring DAC modification
• Ideal for extended GH‑axis signalling, receptor pharmacology, and SAR studies
• Supplied as a stable lyophilised solid for reliable storage
• Unit size: 5 mg per vial
• Each batch undergoes strict internal QC for identity, purity, and appearance
• Provided strictly for laboratory research — not for human or veterinary use

Specifications

• Product name: CJC‑1295 With DAC
• Synonyms: DAC‑modified CJC‑1295; long‑acting GHRH analogue
• Class: Growth hormone–releasing hormone analogue (DAC‑modified)
• Form: Lyophilised powder
• Appearance: White to off‑white solid
• Note: Exact properties may vary by counter‑ion and hydration state. Refer to vial label for batch‑specific details.

Handling & Storage

• Dry storage: Store vials protected from light and moisture
• Reconstitution: Bring vial and diluent to room temperature; reconstitute with Bacteriostatic Water 10 ml; swirl gently — do not vortex
• After reconstitution: Store at 2–8 °C, protect from light, prepare aliquots to minimise freeze–thaw cycles
• Compatibility: Use only within validated research protocols aligned with institutional SOPs and local regulations

Research Applications

CJC‑1295 With DAC is used in controlled in‑vitro systems to investigate:

• Extended GHRHR signalling
• Long‑duration cAMP accumulation
• PKA activation and downstream transcriptional responses
• GH‑axis mechanistic profiling
• DAC‑modified peptide SAR comparisons

Studies focus exclusively on non‑clinical, in‑vitro environments.

Certificate of Analysis (COA)

Each lot of CJC‑1295 With DAC undergoes internal QC checks for identity, purity, and appearance before release. COA available upon request for qualified research institutions.

Synthesis & Quality Assurance

CJC‑1295 With DAC is manufactured through validated peptide‑synthesis processes designed for:

• High purity
• Lot‑to‑lot consistency
• Reliable performance in biochemical and cell‑based assays

Every batch is reviewed under strict internal quality standards.

Related Research Materials

• Ipamorelin 5 mg
• GHRP‑6 5 mg

Why Choose Pep Lab London?

• ISO‑aligned internal QC
• Clinical‑white branding and transparent sourcing
• Research‑only compliance
• Fast UK shipping
• Trusted by GH‑axis and receptor‑signalling research labs

Legal & Safety Notice

Pep Lab London supplies materials strictly for laboratory research. Products are not medications, foods, supplements, or cosmetics, and must not be used in humans or animals. By purchasing, you confirm you are a qualified researcher and will handle the material according to institutional policies and applicable regulations.

Disclaimer

This material is intended solely for in‑vitro research and cannot be:

• Used in clinical studies involving humans
• Administered to humans in any form
• Supplied to any party for human investigational use